JW Life Science

JW Life Science EBITDA per Share

The EBITDA per Share of JW Life Science (234080.KS) as of Nov 4, 2026 is 2,146.93 KRW. In the previous year, EBITDA per Share was 2,347.48 KRW — a change of -8.54% (lower).

EBITDA per Share

2,146.93KRW

YoY

-8.54%

Last updated:

EBITDA per Share of JW Life Science is 2025 2,146.93 KRW. EBITDA per Share of JW Life Science was 2024 2,347.48 KRW. It decreases by -8.54% lower compared to the previous year.

The JW Life Science EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
1,529.59 KRW
Jan 1, 2018
1,519.42 KRW
Jan 1, 2019
1,944.35 KRW
Jan 1, 2020
2,570.49 KRW
Jan 1, 2021
1,919.13 KRW
Jan 1, 2022
1,853.78 KRW
Jan 1, 2023
2,347.48 KRW
Jan 1, 2025
2,146.93 KRW
The JW Life Science EBITDA per Share history
YEAREBITDA per ShareYoY
2,146.93KRW-8.54%
2,347.48KRW+26.63%
1,853.78KRW-3.40%
1,919.13KRW-25.34%
2,570.49KRW+32.20%
1,944.35KRW+27.97%
1,519.42KRW-0.67%
1,529.59KRW+11.09%
1,376.89KRW+15.83%
1,188.69KRW+26.87%
936.94KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JW Life Science Stock analysis

What does JW Life Science do? JW Life Science Corp. manufactures intravenous fluids including basic IV fluids with water, electrolytes, and glucose, nutrient infusion solutions containing amino acids, lipids, proteins, vitamins, and minerals, and special infusion solutions for specific medical cases. The company produces total parenteral nutrition (TPN) products as part of its manufacturing focus. The primary buyers of these products are healthcare providers and hospitals requiring intravenous treatments for patient care. The company serves the medical sector by providing essential fluid and nutrition solutions for clinical use. The firm's product segments are defined by the types of IV fluids and TPN solutions they produce, targeting healthcare institutions that administer intravenous therapies. Basic IV fluids are used for general hydration and electrolyte balance, while nutrient infusion solutions support patient nutrition in critical care settings. Special infusion solutions address unique medical conditions requiring tailored treatments. The company's offerings are integral to hospital and clinic operations in delivering patient care. JW Life Science Corp. generates revenue through the sale of its manufactured intravenous fluid products to healthcare facilities. The company's business model relies on consistent demand for IV fluids and TPN solutions within the medical industry. Its products are distributed to hospitals and clinics that require these essential medical supplies for patient treatment protocols. JW Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JW Life Science stock

EBITDA per Share of JW Life Science is 2,146.93 KRW in 2025.

EBITDA per Share of JW Life Science changed from 2,347.48 KRW to 2,146.93 KRW, representing a -8.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share JW Life Science since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — JW Life Science

All Key Metrics — JW Life Science